default author photo

Ravindre Panchia

Chris Hani Baragwanath Academic Hospital - Perinatal HIV Research Unit

Diepkloof, 1864

South Africa

SCHOLARLY PAPERS

4

DOWNLOADS

430

TOTAL CITATIONS

1

Scholarly Papers (4)

1.

Randomised Trial of a Single Dose of Ad26.COV2.S, BNT162b2 or SARS-CoV-2-rS-PN in Previously Vaccinated and Unvaccinated Adults Living with and without HIV in South Africa: Safety and Immunogenicity

Number of pages: 21 Posted: 14 May 2025
Aurum Institute, South African Medical Research Council - Biostatistics Research Unit, Aurum Institute, Aurum Institute, Aurum Institute, Aurum Institute, Aurum Institute, Aurum Institute, Aurum Institute, Aurum Institute, Chris Hani Baragwanath Academic Hospital - Perinatal HIV Research Unit, Aurum Institute, The Aurum Institute, Aurum Institute, Aurum Institute, Aurum Institute, Aurum Institute, National Health Laboratory Services (NHLS) - National Institute for Communicable Diseases, University of the Witwatersrand, University of Cape Town (UCT) - Institute of Infectious Disease and Molecular Medicine, University of Cape Town (UCT) - Institute of Infectious Disease and Molecular Medicine, Government of India - Translational Health Science & Technology Institute (THSTI), Government of India - Translational Health Science & Technology Institute (THSTI), Government of India - Translational Health Science & Technology Institute (THSTI), Aurum Institute, South African Medical Research Council, South African Medical Research Council, Aurum Institute, Aurum Institute, Aurum Institute and Independent
Downloads 136 (540,814)

Abstract:

Loading...

randomised controlled trial, clinical trial, people living with HIV, COVID-19 vaccines, booster vaccines

2.

Estimation of Background HIV Incidence Using the Recent Infection Testing Algorithm (Rita): Experiences from the Insight HIV Prevention Study in Six Sub-Saharan African Countries

Number of pages: 32 Posted: 14 Aug 2024
University of Washington, University of Washington, University of Alabama at Birmingham, University of Washington, Johns Hopkins University, University of the Witwatersrand - Reproductive Health and HIV Research Unit (RHRU), University of Cape Town (UCT), University of Cape Town (UCT), University of Cape Town (UCT), University of Cape Town (UCT), Qhakaza Mbokodo Research Clinic, Human Sciences Research Council (HSRC) - Centre for Community Based Research, Human Sciences Research Council (HSRC), Foundation for Professional Development, Wits Maternal Adolescent and Child Health Research, Setshaba Research Centre, Chris Hani Baragwanath Academic Hospital - Perinatal HIV Research Unit, University of the Witwatersrand, Klerksdorp-Tshepong Hospital Complex, Aurum Rustenburg Clinical Research Centre, Madibeng Centre for Research, South African Medical Research Council, Columbia University - ICAP, Kenya Medical Research Institute (KEMRI), Johns Hopkins Bloomberg School of Public Health, Malawi, UNC Global Projects, Bio Analytical Research Corporation South Africa (BARC SA), University of Washington, University of Washington, Fred Hutchinson Cancer Research Center and Independent
Downloads 126 (592,433)
Citation 1

Abstract:

Loading...

HIV recency, HIV PRE-EXPOSURE PROPHYLAXIS, clinical trial design

3.

Cabotegravir for Prevention of HIV-1 in Women: Results From HPTN 084, a Phase III, Randomised Controlled Trial

THELANCET-D-22-01258
Number of pages: 186 Posted: 25 Mar 2022
University of the Witwatersrand - Reproductive Health and HIV Research Unit (RHRU), Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Stellenbosch University, Kenya Medical Research Institute (KEMRI), CeSHHAR Zimbabwe, South African Medical Research Council - HIV Prevention and Vaccine Research Unit, Blantyre International University, Botswana Harvard AIDS Institute Partnership (BHP), University of Zimbabwe - Clinical Trials Research Centre, University of the Witwatersrand, South African Medical Research Council - HIV Prevention and Vaccine Research Unit, Government of Uganda - Uganda Virus Research Institute (UVRI), University of Zimbabwe - Clinical Trials Research Centre, University of Zimbabwe - Clinical Trials Research Centre, Baylor University - Children’s Foundation-Eswatini, University of Cape Town (UCT) - Desmond Tutu HIV Centre, Makerere University, Columbia University - ICAP, Chris Hani Baragwanath Academic Hospital - Perinatal HIV Research Unit, South African Medical Research Council - HIV Prevention and Vaccine Research Unit, University of Zimbabwe - Clinical Trials Research Centre, FHI 360, FHI 360, University of the Witwatersrand, University of Colorado, Aurora - Anschutz Medical Campus, Johns Hopkins University - Department of Pathology, Johns Hopkins University - Department of Pathology, Johns Hopkins University - School of Medicine, Johns Hopkins University - Department of Pathology, Johns Hopkins University - School of Medicine, FHI 360, University of the Witwatersrand - Faculty of Health Sciences, University of the Witwatersrand, Johns Hopkins University - School of Medicine, Fred Hutchinson Cancer Research Center - Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center - Statistical Center for HIV/AIDS Research and Prevention, FHI 360, FHI 360, Stroger Hospital of Cook County, FHI 360, FHI 360, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Gilead Sciences, ViiV Healthcare Ltd., ViiV Healthcare Ltd., ViiV Healthcare Ltd., Fred Hutchinson Cancer Research Center - Statistical Center for HIV/AIDS Research and Prevention, University of North Carolina (UNC) at Chapel Hill, University of North Carolina (UNC) at Chapel Hill - UNC-Project Malawi and affiliation not provided to SSRN
Downloads 112 (635,507)

Abstract:

Loading...

4.

Tail-Phase Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in HIV-Uninfected Adults: HPTN 077

Number of pages: 169 Posted: 05 Sep 2019
University of California, Los Angeles (UCLA) - UCLA Center for Clinical AIDS Research and Education, Fred Hutchinson Cancer Research Center - Statistical Center for HIV/AIDS Research and Prevention, University of North Carolina (UNC) at Chapel Hill, - Evandro Chagas National Institute of Infectious Diseases (INI), University of KwaZulu-Natal - Centre for the AIDS Programme of Research in South Africa (CAPRISA), San Francisco Department of Health - Bridge HIV, George Washington University - Department of Epidemiology, University of North Carolina (UNC) at Chapel Hill - UNC-Project Malawi, Chris Hani Baragwanath Academic Hospital - Perinatal HIV Research Unit, Fred Hutchinson Cancer Research Center - Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center - Statistical Center for HIV/AIDS Research and Prevention, Johns Hopkins University - School of Medicine, Johns Hopkins University - School of Medicine, Johns Hopkins University - Department of Pathology, University of California, Los Angeles (UCLA) - UCLA Center for Clinical AIDS Research and Education, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institutes of Health (NIH), ViiV Healthcare Ltd., ViiV Healthcare Ltd., University of North Carolina (UNC) at Chapel Hill, FHI 360 and Johns Hopkins University - School of Medicine
Downloads 56 (1,000,027)

Abstract:

Loading...

HIV Prevention, Cabotegravir, PrEP, Pre-Exposure Prophylaxis